Assessment and modification of cardiovascular disease risk in the HIV-infected individual

Future Virology

Volumn 6, Issue 3, 2011, Pages 307-320

  Ross, Allison C ^a   McComsey, Grace A ^b,c  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

antiretroviral therapy; cardiovascular disease; dyslipidemia; HIV infection; inflammation; nucleoside reverse transcriptase inhibitors; protease inhibitors

Indexed keywords

25 HYDROXYVITAMIN D; ABACAVIR; AMFEBUTAMONE; ATAZANAVIR; C REACTIVE PROTEIN; CYTOCHROME P450; DIDANOSINE; EZETIMIBE; FISH OIL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINE GUM; OMEGA 3 FATTY ACID; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; TRIACYLGLYCEROL; VARENICLINE; VITAMIN D;

ACUTE HEART INFARCTION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; DIABETES MELLITUS; DYSLIPIDEMIA; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; IMMUNE STATUS; LIPODYSTROPHY; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SMOKING CESSATION; STROKE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79953299568     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.11.8     Document Type: Review

References (116)

1. Lohse N, Hansen AB, Pedersen G et al.: Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann. Intern. Med. 146(2), 87-95 (2007).
2. Walensky RP, Paltiel AD, Losina E et al.: The survival benefits of AIDS treatment in the United States. J. Infect. Dis. 194(1), 11-19 (2006).
3. Lewden C, Chene G, Morlat P et al.: HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr. 46(1), 72-77 (2007).
4. Obel N, Thomsen HF, Kronborg G et al.: Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin. Infect. Dis. 44(12), 1625-1631 (2007).
5. Triant VA, Lee H, Hadigan C, Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab. 92(7), 2506-2512 (2007). Demonstrated that HIV-infected patients are at a higher risk of cardiovascular disease (CVD) compared with uninfected controls, even after adjusting for traditional risk factors.
6. Friis-Moller N, Sabin CA, Weber R et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349(21), 1993-2003 (2003). Demonstrated the high prevalence of traditional CVD risk factors among HIV-infected individuals. Furthermore, the data showed that antiretroviral therapy (ART) was independently associated with a 26% relative increase in the myocardial infarction rate per year of exposure during the first 4-6 years of use.
7. Kaplan RC, Kingsley LA, Sharrett AR et al.: Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin. Infect. Dis. 45(8), 1074-1081 (2007).
8. Riddler SA, Li X, Chu H et al.: Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 8(5), 280-287 (2007).
9. Shafran SD, Mashinter LD, Roberts SE: The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 6(6), 421-425 (2005).
10. Friis-Moller N, Reiss P, Sabin CA et al.: Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356(17), 1723-1735 (2007). Follow-up Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study evaluated classes of ART and found that current or recent use of abacavir and didanosine were associated with an increased risk of myocardial infarction.
11. Currier JS, Kendall MA, Zackin R et al.: Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 19(9), 927-933 (2005).
12. Lundgren JD, Neuhaus J, Babiker A et al.: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22(14), F17-F24 (2008).
13. Lang S, Mary-Krause M, Cotte L et al.: Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch. Intern. Med. 170(14), 1228-1238
14. Martin A, Bloch M, Amin J et al.: Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir - lamivudine: a randomized, 96-week trial. Clin. Infect. Dis. 49(10), 1591-1601 (2009).
15. Constance B, Ribaudo H, Zheng E et al.: No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001 [abstract 721]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. CA, USA 16-19 February, 2010.
16. Bedimo R, Westfall A, Drechsler H, Tebas P: Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era [abstract MOAB202]. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa 19-22 July, 2009.
17. McComsey G, Smith K, Patel P et al.: Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtricitabine: the HEAT study [abstract 732]. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA 8-11 February, (2009).
18. th Infectious Diseases Society of America Annual Conference. Vancouver, British Columbia, Canada 21-24 October, 2010.
19. Satchell CS, Cotter AG, O'Connor EF et al.: Platelet function and HIV: a case-control study. AIDS 24(5), 649-657 (2010).
20. Isomaa B, Almgren P, Tuomi T et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24(4), 683-689 (2001).
21. Mondy KE, De Las Fuentes L, Waggoner A et al.: Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. AIDS 22(7), 849-856 (2008).
22. Mangili A, Jacobson DL, Gerrior J, Polak Jf, Gorbach SL, Wanke CA: Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin. Infect. Dis. 44(10), 1368-1374 (2007).
23. Van Vonderen MG, Smulders YM, Stehouwer CD et al.: Carotid intima-media thickness and arterial stiffness in HIVinfected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J. Acquir. Immune Defic. Syndr. 50(2), 153-161 (2009).
24. Ross AC, Armentrout R, O'Riordan MA et al.: Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J. Acquir. Immune Defic. Syndr. 49, 499-506 (2008).
25. Sattler FR, Qian D, Louie S et al.: Elevated blood pressure in subjects with lipodystrophy. AIDS 15(15), 2001-2010 (2001).
26. Modrich L, Scherzer R, Zolopa A et al.: Factors associated with mortality in the study of fat dedistribution and metabolic change in HIV infection (abstract 706). Presented at: 16th Conference on Retroviruses and Opportunistic Infections. CA, USA 8-11 February, 2009.
27. Lorenz MW, Stephan C, Harmjanz A et al.: Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 196(2), 720-726 (2008).
28. Grunfeld C, Delaney JA, Wanke C et al.: Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 23(14), 1841-1849 (2009).
29. Hsue PY, Hunt PW, Schnell A et al.: Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 23(9), 1059-1067 (2009).
30. Bonilla H, Mcshannic J, Chua D, McComsey G: Cardiovascular disease (CVD) and inflammatory markers in long term non-progressors (LTNP) [abstract H-220]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA 12-15 September, 2010.
31. + T-cell-guided interruption of ART. Data suggest that continual viral suppression decreases overall mortality and CVD-associated events.
32. Kuller LH, Tracy R, Belloso W et al.: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5(10), E203 (2008). Showed that inflammation and coagulatory disorders are partly responsible for the increased CVD risk among HIV-infected people.
33. Ananworanich J, Gayet-Ageron A, Le Braz M et al.: CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 368(9534), 459-465 (2006).
34. Ross AC, Rizk N, O'Riordan MA et al.: Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin. Infect. Dis. 49(7), 1119-1127 (2009).
35. Torriani FJ, Komarow L, Parker RA et al.: Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J. Am. Coll. Cardiol. 52(7), 569-576 (2008). Endothelial function improved after starting ART-naive subjects on ART.
36. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM: Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med. 10(2), 79-87 (2009).
37. + T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 22(13), 1615-1624 (2008).
38. Lo J, Abbara S, Shturman L et al.: Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 24(2), 243-253 (2010).
39. Jerico C, Knobel H, Calvo N et al.: Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 37(3), 812-817 (2006).
40. Cannell JJ, Hollis BW, Sorenson MB, Taft TN, Anderson JJ: Athletic performance and vitamin D. Med. Sci. Sports Exerc. 41(5), 1102-1110 (2009).
41. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V: Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am. J. Clin. Nutr. 87(1), 136-141 (2008).
42. Liu J, Cao Z, Zhang Z, Zhou S, Ye Z: A comparative study on several models of experimental renal calcium oxalate stones formation in rats. J. Huazhong Univ. Sci. Technol. Med. Sci. 27(1), 83-87 (2007).
43. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R: Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 83(4), 754-759 (2006).
44. Shea MK, Booth SL, Massaro JM et al.: Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am. J. Epidemiol. 167(3), 313-320 (2008).
45. Martins D, Wolf M, Pan D et al.: Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 167(11), 1159-1165 (2007).
46. Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am. J. Hypertens. 20(7), 713-719 (2007).
47. Giovannucci E, Liu Y, Hollis BW, Rimm EB: 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168(11), 1174-1180 (2008).
48. Wang TJ, Pencina MJ, Booth SL et al.: Vitamin D deficiency and risk of cardiovascular disease. Circulation 117(4), 503-511 (2008).
49. London GM, Guerin AP, Verbeke FH et al.: Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J. Am. Soc. Nephrol. 18(2), 613-620 (2007).
50. Targher G, Bertolini L, Padovani R et al.: Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among Type 2 diabetic patients. Clin. Endocrinol. (Oxf.) 65(5), 593-597 (2006).
51. Khazai N, Judd SE, Tangpricha V: Calcium and vitamin D: skeletal and extraskeletal health. Curr. Rheumatol. Rep. 10(2), 110-117 (2008).
52. Mathieu C, Gysemans C, Giulietti A, Bouillon R: Vitamin D and diabetes. Diabetologia 48(7), 1247-1257 (2005).
53. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R: Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 83(4), 754-759 (2006).
54. Rahman A, Hershey S, Ahmed S, Nibbelink K, Simpson RU: Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J. Steroid Biochem. Mol. Biol. 103(3-5), 416-419 (2007).
55. Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU: Functional vitamin D receptor (VDR) in the T-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 149(2), 558-564 (2008).
56. Simpson RU, Hershey SH, Nibbelink KA: Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J. Steroid Biochem. Mol. Biol. 103(3-5), 521-524 (2007).
57. Holick MF: The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol. Aspects Med. 29(6), 361-368 (2008).
58. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M et al.: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res. Human Retroviruses 24(11), 1375-1382 (2008).
59. Rodriguez M, Daniels B, Gunawardene S, Robbins GK: High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res. Human Retroviruses 25(1), 9-14 (2009).
60. Childs K, Fishman S, Factor S, Dieterich D, Mullen M, Branch A: First report of dose/response data of HIV-infected men treated with vitamin D3 supplements (abstract 756). Presented at: 16th Conference on Retroviruses and Opportunistic Infections. CA, USA27 February-2 March, 2009.
61. Brown TT, McComsey GA: Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir. Ther. 15(3), 425-429 (2010).
62. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS: HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 17(4), 513-520 (2003).
63. Ross A, Judd S, Kumari M et al.: Vitamin D is linked to carotid intima-media thickness, inflammation, and immune reconstitution in HIV-Infected individuals [abstract 1869]. Presented at: 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver, British Columbia, Canada, 21-24 October, 2010.
64. Dong Y, Stalmmann-Jorgensen I, Pollock N et al.: A 16-week randomized clinical trial of 2,000 IU daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J. Clin. Endocrinol. Metab. DOI:10.1210/jc.2010-0606 (2011) (Epub ahead of print).
65. Tarcin O, Yavuz DG, Ozben B et al.: Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J. Clin. Endocrinol. Metab. 94(10), 4023-4030 (2009).
66. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD: Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 25(3), 320-325 (2008).
67. Law MG, Friis-Moller N, El-Sadr WM et al.: The use of the Framingham equation to predict myocardial infarctions in HIVinfected patients: comparison with observed events in the D:A:D study. HIV Med. 7(4), 218-230 (2006).
68. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE: Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 131(2), 446-452 (2007).
69. Fiore MC: Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir. Care 45(10), 1196-1199 (2000).
70. Stein JH, Hadigan CM, Brown TT et al.: Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation 118(2), E54-E60 (2008).
71. Tornero C, Mafe C: Varenicline and antiretroviral therapy in patients with HIV. J. Acquir. Immune Defic. Syndr. 52(5), 656 (2009).
72. Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM: Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin. Pharmacol. Ther. 81(1), 69-75 (2007).
73. Hesse LM, Venkatakrishnan K, Court MH et al.: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 28(10), 1176-1183 (2000).
74. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
75. Mallolas J, Podzamczer D, Milinkovic A et al.: Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J. Acquir. Immune Defic. Syndr. 51(1), 29-36 (2009).
76. Malan Dr, Krantz E, David N, Wirtz V, Hammond J, Mcgrath D: Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J. Acquir. Immune Defic. Syndr. 47(2), 161-167 (2008).
77. Colafigli M, Di Giambenedetto S, Bracciale L, Tamburrini E, Cauda R, De Luca A: Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med. 9(3), 172-179 (2008).
78. Madruga Jr, Cassetti I, Suleiman JM et al.: The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin. Trials 8(6), 381-390 (2007).
79. Tebas P, Henry WK, Matining R et al.: Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS ONE 3(4), E2021 (2008).
80. Calza L, Manfredi R, Colangeli V et al.: Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 19(10), 1051-1058 (2005).
81. Calza L, Manfredi R, Chiodo F: Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 17(6), 851-859 (2003).
82. Townsend ML, Hollowell SB, Bhalodia J, Wilson KH, Kaye KS, Johnson MD: A comparison of the effectiveness of lipidlowering therapy between HIV- and non-HIVinfected subjects with hyperlipidaemia. Int. J. STD AIDS 18(12), 851-855 (2007).
83. Silverberg MJ, Leyden W, Hurley L et al.: Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann. Intern. Med. 150(5), 301-313 (2009).
84. Johns KW, Bennett MT, Bondy GP: Are HIV positive patients resistant to statin therapy? Lipids Health Dis. 6, 27 (2007).
85. Dalton TA, Berry RS: Hepatotoxicity associated with sustained-release niacin. Am. J. Med. 93(1), 102-104 (1992).
86. Garg A, Grundy SM: Nicotinic acid as therapy for dyslipidemia in non-insulindependent diabetes mellitus. JAMA 264(6), 723-726 (1990).
87. Brown TT, Cole SR, Li X et al.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165(10), 1179-1184 (2005).
88. Elam MB, Hunninghake DB, Davis KB et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284(10), 1263-1270 (2000).
89. Grundy SM, Vega GL, Mcgovern ME et al.: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with Type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med. 162(14), 1568-1576 (2002).
90. Gerber MT, Mondy KE, Yarasheski KE et al.: Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin. Infect. Dis. 39(3), 419-425 (2004).
91. Dube MP, Wu JW, Aberg JA et al.: Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir. Ther. 11(8), 1081-1089 (2006).
92. Chow DC, Stein JH, Seto TB et al.: Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. AIDS 24(7), 1019-1023 (2010).
93. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al.: Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 16(4), 569-577 (2002).
94. Negredo E, Molto J, Puig J et al.: Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 20(17), 2159-2164 (2006).
95. Mastroianni CM, D'Ettorre G, Forcina G et al.: Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS 15(6), 820-821 (2001).
96. Dube MP, Stein JH, Aberg JA et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis. 37(5), 613-627 (2003). Offers guidelines for the evaluation and management of dyslipidemia in HIV.
97. De Truchis P, Kirstetter M, Perier A et al.: Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J. Acquir. Immune Defic. Syndr. 44(3), 278-285 (2007).
98. Gerber JG, Kitch DW, Fichtenbaum CJ et al.: Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J. Acquir. Immune Defic. Syndr. 47(4), 459-466 (2008).
99. Carr A, Hudson J, Chuah J et al.: HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 15(14), 1811-1822 (2001).
100. Aberg JA, Zackin RA, Brobst SW et al.: A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res. Hum. Retroviruses 21(9), 757-767 (2005).
101. Miller J, Brown D, Amin J et al.: A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 16(16), 2195-2200 (2002).
102. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG: Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15(12), 1503-1508 (2001).
103. Doser N, Kubli S, Telenti A et al.: Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS 16(14), 1982-1983 (2002).
104. Volberding PA, Murphy RL, Barbaro G et al.: The Pavia consensus statement. AIDS 17 (Suppl. 1), S170-S179 (2003).
105. Fitch KV, Anderson EJ, Hubbard JL et al.: Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 20(14), 1843-1850 (2006).
106. Gupta SK, Johnson RM, Mather KJ et al.: Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. AIDS 24(9), 1377-1380 (2010).
107. Mora S, Ridker PM: Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am. J. Cardiol. 97(2A), 33A-41A (2006). Suggests that statin use for its antiinflammatory properties may prove useful in decreasing CVD risk.
108. Hileman C, Carman T, Storer N, Harrill D, Mccomsey G: Omega 3 fatty acids do not improve endothelial function in virologically suppressed HIV-infected adults: a placebo-controlled trial [abstract 1089]. Presented at: 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver, British Columbia, Canada 21-24 October, 2010.
109. Hileman CO, Carman TL, Gripshover BM et al.: Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults. AIDS 24(12), 1958-1961 (2010).
110. Giuliano Ide C, De Freitas SF, De Souza M, Caramelli B: Subclinic atherosclerosis and cardiovascular risk factors in HIV-infected children: PERI study. Coronary Artery Disease 19(3), 167-172 (2008).
111. Mccomsey GA, O'Riordan M, Hazen SL et al.: Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 21(8), 921-927 (2007).
112. Charakida M, Donald AE, Green H et al.: Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 112(1), 103-109 (2005).
113. Ross A, Storer N, O'Riordan M, Labbato D, Dogra V, McComsey G: Longitudinal changes in carotid intima-media thickness (cIMT) in HIV-infected children [abstract 153]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA 27 February-2 March, 2011.
114. Ross AC, O'Riordan MA, Storer N, Dogra V, Mccomsey GA: Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis 211(2), 492-498 (2010).
115. Effros RB, Fletcher CV, Gebo K et al.: Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin. Infect. Dis. 47(4), 542-553 (2008).
116. Moore T, Cohen M, Furberg C: Strong safety signal seen for new varenicline risks. The Institute for Safe Medication Practices. Horsham, PA, USA (2008) www.ismp.org/docs/vareniclineStudy.asp